http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PL-426138-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_54d112629ffe022ebab46c4bee61f80a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f9f8c6f6d2ff67cbe53a1ed5e5cb527 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2496-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-26 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-7233 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56911 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 |
| filingDate | 2018-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_deb3f669ee41973005c909117af4e7ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_301bd5b1069e6ccea7bed4bc72263748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f7cbccbdfb0fd108d1a788e2b8b4e12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7311db63d5c228040f965483c740398e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05253d507cb60ed7ca912c0c612e47be http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb26fe8476d32eb4bda8d0597cfbb0a0 |
| publicationDate | 2020-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | PL-426138-A1 |
| titleOfInvention | Lyme disease diagnosis method, Lyme arthritis differential diagnosis kit, Lysophosphatidylethanolamine for use as a biomarker, Lyme disease diagnosis kit and Lyme arthritis differential diagnosis kit |
| abstract | The subject of the application is a method of in vitro diagnosis of Lyme disease and a method of differential diagnosis in vitro of Lyme arthritis versus rheumatoid arthritis, in which methods in a sample from an individual are determined for the level of myristic acid-containing lysophosphatidylethanolamine (LysoPE) (14: 0), and compared to yes the level of lysophosphatidylethanolamine with the level of lysophosphatidylethanolamine containing myristic acid in the reference sample; wherein a level of myristic acid containing lysophosphatidylethanolamine higher than that of said reference sample indicates that the subject is suffering from Lyme disease. The subject of the application is also lysophosphatidylethanolamine, containing myristic acid for use as a biomarker of Lyme disease, as a biomarker of Lyme arthritis, as a biomarker for the differential diagnosis of Lyme arthritis versus rheumatoid arthritis, as a biomarker of neuroborreliosis. The subject of the application is also an in vitro diagnosis kit for Lyme disease and an in vitro differential diagnosis kit for Lyme arthritis, the kits containing a lysophosphatidylethanolamine-containing agent containing myristic acid and instructions for diagnosis methods. |
| priorityDate | 2018-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11005 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407295578 |
Total number of triples: 25.